VPS51, VPS51 subunit of GARP complex, 738

N. diseases: 292; N. variants: 0
Disease: Endothelial dysfunction ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.100 Biomarker phenotype BEFREE Ang II (angiotensin II), a key pro-hypertensive hormone, mediates target organ consequences such as endothelial dysfunction and cardiac hypertrophy. 31838904 2020
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.100 Biomarker phenotype BEFREE In Ang II-infused mice, mPGES-1 deletion prevented all of the following: (1) the augmented wall:lumen ratio, vascular stiffness, and altered elastin structure; (2) the increased gene expression of profibrotic and proinflammatory markers; (3) the increased vasoconstrictor responses and endothelial dysfunction; (4) the increased NADPH oxidase activity and the diminished mitochondrial membrane potential; and (5) the increased reactive oxygen species generation and reduced NO bioavailability. 29891646 2018
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.100 Biomarker phenotype BEFREE Anti-TCRγδ antibody-induced γδ T-cell depletion blunted Ang II-induced SBP rise and endothelial dysfunction (<i>P</i><0.05), compared with isotype antibody-treated Ang II-infused mice. 28330983 2017
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.100 Biomarker phenotype BEFREE Our results demonstrate that in Ang II-induced hypertensive rats, puerarin protects against endothelial dysfunction and end organ damage with a mild reduction in SBP, and that the cardiovascular beneficial effects of puerarin may be in part attributed to its anti-oxidant and upregulation of phosphor-eNOS. 28060542 2017
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.100 Biomarker phenotype BEFREE BM transplantation revealed a role for immune cells in Ang II-induced BP elevation, and for both vascular and immune cell MMP2 in Ang II-induced endothelial dysfunction. 29016715 2017
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.100 AlteredExpression phenotype BEFREE Ang-2 and sTie-2 plasma levels are increased in pediatric OSA and obesity, particularly when endothelial dysfunction or insulin resistance is detectable, and appear to decrease upon OSA treatment. 28474375 2017
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.100 Biomarker phenotype BEFREE In mice, deletion of P2Y6R attenuated Ang II-induced increase in blood pressure, vascular remodeling, oxidative stress, and endothelial dysfunction. 26787451 2016
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.100 Biomarker phenotype BEFREE Angiotensin (Ang) II plays an important role in the process of endothelial dysfunction in acute lung injury (ALI) and is degraded by angiotensin-converting enzyme2 (ACE2). 25200929 2015
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.100 Biomarker phenotype BEFREE Angiotensin II (Ang II) is essential for endothelial progenitor cells (EPCs) function as Ang-II-induced oxidative stress causes senescence of EPCs and endothelial dysfunction and Ang II type 1 receptor blockers increase EPCs. 21654754 2011
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.100 Biomarker phenotype BEFREE One of the main effectors of endothelial dysfunction is ANG II, and pharmacological approaches to limit ANG II bioactivity remain the cornerstone of cardiovascular therapeutics. 18660448 2008
CUI: C0856169
Disease: Endothelial dysfunction
Endothelial dysfunction 		0.100 Biomarker phenotype BEFREE Ang II-induced endothelial dysfunction is associated with increased oxidative stress and vascular xanthine oxidase activity. 11230310 2001